INTRODUCTION
Despite major advances in treatment modalities, gastric cancer (GC) remains the fourth most common cancer in the world and the second cause of cancer related mortality worldwide (1, 2) . Several factors including Helicobacter Pylori infection, diet, tobacco use, obesity, and genetic alterations have been linked to the onset of gastric cancer (3) . Existing treatment strategies include surgery, chemotherapy and molecular targeted therapy but are limited by tumor recurrence and chemoresistance (4) . Even though GC has been considered as a chemosensitive tumor for many years, no significant progress in its management has resulted within the last two decades with only few patients experiencing complete pathologic responses to chemotherapy (5, 6) . Hence, novel approaches to enhance the effects of chemotherapeutic drugs and improve the existing standard of care are urgently needed.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that were first discovered 20 years ago (7) . There are three isoforms of PPAR; PPARα, PPARβ/δ (also known as PPARβ or PPARδ) and PPARγ (8) . These have been found in all the mammalian species that have been examined to date (9, 10) . PPARγ is highly expressed in cancer cells and treatment with PPARγ ligands can induce cell differentiation and apoptosis (11) (12) (13) . Existing endogenous ligands for PPARγ include polyunsaturated fatty acids and the eicosanoids 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), 13-hydroxyoctadecadienoic acid, and 15-hydroxyeicosatetraenoic acid (14, 15) . Detailed analysis by cancer researchers has revealed that PPARγ is overexpressed in patients with gastric carcinoma (16) . The same study also suggested that PPARγ might be a molecular marker for the development of gastric cancer from chronic gastritis. Other studies have shown that PPARγ plays a protective role in gastric carcinogenesis and activation of the receptor has a chemo-preventive effect (17) . PPAR initiates transcription by hetero-dimerization with a member of the retinoid X receptor family (RXR) (18) . This is succeeded by binding to a peroxisome proliferator response element (PPRE) within the regulatory region of target genes which leads to transcriptional activation or repression (19, 20) . Though it remains unclear whether PPARs are oncogenes or tumor suppressors, research has focused on this receptor due to its involvement in various metabolic disorders that are known to be associated with cancer risk (21-23).
Flavonoids are non-essential dietary factors that are abundantly present in fruits, vegetables, seeds, nuts, tea and red wine. Many herbs containing flavonoids have been used as traditional medicine (24) (25) (26) . Quercetin is one such bio-flavonoid, known to have several biological effects, including anti-inflammatory and anti-tumor effects in malignant cancer cells (27) . Recent studies have shown that quercetin could alter the morphology and induce apoptosis of gastric cancer cells (28). Isorhamnetin (IH), an immediate metabolite of quercetin, also called 3′-O-methylquercetin, has been under attention for its anti-inflammatory and antiproliferative properties in a number of cancers, including colorectal, skin and lung cancers (29) (30) (31) . Prior studies have focused on quercetin as an anti-cancer agent, but recent research has shown that isorhamnetin can induce higher cytotoxicity in tumor cells as compared to quercetin (29) . For example, it was found that aflatoxin B1 (AFB1)-mediated ROS was inhibited significantly by isorhamnetin when compared to quercetin in hepatocellular carcinoma cells (32) .
Because of the critical role of PPARγ in GC proliferation, survival, invasion, and metastasis, we investigated whether IH can mediate its anti-proliferative and pro-apoptotic effects in GC cells and xenograft model through the activation of the PPARγ signaling cascade. Alongside testing the effects of IH in GC cells and xenograft mouse model, we also tested the hypothesis of PPARγ activation in a virtual predictive tumor cell system to explore if IH is mediating its effects primarily through PPARγ activation. The predictive epithelial tumor cell platform has been employed to get an insight into how a particular drug individually, or in combination, impacts various cancer phenotypes across different tumor profiles. Thus, our novel approach of combining predictive virtual testing with guided experimental validations is helpful in understanding the mechanism of action and efficacy of novel compounds on physiological endpoints. 
EXPERIMENTAL PROCEDURES

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
The anti-proliferative effect of IH against various GC cells was determined by the MTT dye uptake method. Briefly, the cells (5x10 3 per well) were incubated in triplicate in a 96-well plate in the presence or absence of indicated concentrations of IH in a final volume of 0.2 mL for different time intervals at 37°C. Thereafter, 20 mL MTT solution (5 mg/mL in PBS) was added to each well. After a 4 h incubation in the dark at 37°C, 0.1 mL lysis buffer (20% SDS, 50% dimethylformamide) was added; incubated for 2 h at 37°C, followed by measurement of optical density at 570 nm by Tecan plate reader (Durham, NC, USA).
Molecular docking analysis
An X-ray crystallography structure of PPAR-γ (PDB ID: 2Q5S) was obtained from the RCSB Protein Data Bank. This structure was selected because it has a relatively good resolution of 2.05Å, with a R value of 0.199 and R free value of 0.245. The protein file contains two copies of PPAR-γ. The first copy, chain A was removed because it contains less residues than the second copy, chain B. The ligand associated with chain A and all water molecules were also removed. The remaining protein chain and its associated ligand were then processed using the default settings for the "Protonate 3D" feature in the software Molecular Operating Environment (MOE) to add hydrogen atoms and determine the ionization state of the residues. Molecular docking of IH to PPAR-γ was then performed using the Dock feature in MOE. The "Alpha PMI" algorithm was used to generate 250 different poses for IH. Alpha HB scoring function was used to rank these poses. The top 10 poses were retained and further refined by energy minimization. The MMFF94x forcefield using Reaction Field model was used for the energy minimization. Side chains of residues with 6Å from the ligand were allowed to move during energy minimization. After energy minimization, the pose with the best interaction energy with the receptor was retained, as described previously (33) . PPARγ competitive binding assay A binding assay was performed to test if IH could competitively bind to PPARγ using LanthaScreen™ TR-FRET PPARγ Competitive Binding Assay kit (Invitrogen Corporation, CA 92008). A terbium-labeled anti-GST antibody was used to indirectly label a nuclear receptor (NR) by binding to its GST tag. When a fluorescent ligand (tracer) binds to the receptor, energy transfer from the antibody to the tracer occurs, and a high TR-FRET ratio is observed. Competitive ligand binding to the NR is detected by a test compound"s ability to displace the tracer from the NR, which results in a loss of FRET signal between the antibody and the tracer. The assay was performed with various concentrations of IH as described in figure legends. The curve was plotted using a sigmoidal dose-response equation with varying slope using Prism® software from GraphPad™ Software, Inc.
Flow cytometric analysis
To determine the effect of IH on the cell cycle, GC cells were first seeded at a density of 2x10 5 cells per well in a 6-well titre plate and incubated at 37°C overnight. They were then exposed to IH for the various time intervals as described in figure legends. Thereafter cells were washed, fixed with 70% ethanol, and incubated for 30 min at 37°C with 0.1% RNase-A in PBS. Cells were then washed again, resuspended, and stained in PBS containing 25μg/ml propidium iodide (PI) for 30min at room temperature. Cell distribution across the cell cycle was analyzed with a CyAn ADP flow cytometer (Dako Cytomation) as described previously (34) . Annexin V assay GC cells were first seeded at a density of 2x10 5 cells per well in a 6-well titre plate and allowed to incubate at 37°C overnight. After treatment with IH for the indicated time intervals, cells were trypsinized, washed with binding buffer, and resuspended in annexin V-FITC-added binding buffer for 15 minutes under dark conditions and washed and stained with PI containing binding buffer. The samples were then analyzed immediately by flow cytometry as described previously (34) .
Wound healing assay
The migration of cells was investigated using "wound-healing" assay. GC cells were seeded in a 6-well microtitre plate until about 80% confluent. A "wound" was created using a pipette tip and each well was rinsed with PBS to remove detached cells. The cells were pretreated with GW9662, a pharmacological PPAR-γ specific inhibitor for 2h, followed by incubation with IH for 8 h. The microscopic observation of the cells was recorded as described previously (35) .
Invasion assay
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The BD BioCoat Tumor Invasion system is a chamber that has a light-tight polyethylene terephthalate membrane with 8μm diameter pores and is coated with a reconstituted basement membrane gel (BD Biosciences). 2x10 5 GC cells were suspended in serumfree DMEM media and seeded into the Matrigel transwell chambers. The cells were pretreated with GW9662, a pharmacological PPAR-γ specific inhibitor for 2 h, followed by incubation with IH for 8 h. After incubation, the outer surfaces of the transwell chambers were wiped with cotton swabs and the invading cells were fixed and stained with crystal violet solution. The invading cells were then counted in 5 randomly selected areas under microscopic observation as described previously (35) .
Luciferase assay
The activity of PPAR-γ was investigated using luciferase assay as described previously (36). Firstly, GC cells were seeded at density of 5x10 4 cells per well in a 12-well microtiter plate followed by overnight incubation. The cells were incubated in serum free DMEM medium for at least 1 h before transfection with pPPREtk-Luc (three PPREs from rat acyl-CoA oxidase promoter under the control of the Herpes simplex virus thymidine kinase promoter). For PPARs study, the cells were transfected with each of GAL4-PPAR-α LBD, GAL4-PPAR-β LBD and GAL4-PPAR-γ LBD plasmids (a generous gift from Dr. Javier F. Piedrafita, Torrey Pines Institute for Molecular Studies, San Diego, CA, USA), together with GAL4-Luc. For dominant negative transfection, the cells were transfected with PPAR-γ mutant or pCMX-PPARγ plasmid (a cDNA clone encoding the mouse PPAR-γ; a generous gift from Dr. Ronald M. Evans, The Salk Institute for Biological Studies, San Diego, CA, USA), together with pPPRE-tk-Luc. Cells were lysed in reporter lysis buffer and luciferase activity was measured with a Tecan (Durham, NC, USA) plate reader and normalized against β-galactosidase activity.
Western blot analysis
For detection of various proteins, GC cells were first seeded at a density of 3x10 5 cells per well on a 6 well micro-titer plate and treated with IH for different time intervals. The cells were then washed with 1X PBS and incubated on ice for 30 min in 0.05 ml lysis buffer (2.0 mM Tris (pH 7.4), 2.50 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton X-100, 0.01 mg/mL aprotinin, 0.005 mg/mL leupeptin, 0.4 mM PMSF, and 4 mM Na 3 VO 4 ). The lysate was then centrifuged at 12,000 rpm for 3 minutes to remove the cell debris after which the supernatant was collected. Whole-cell extract protein (ranging from 30-70 μg) was resolved on 12%, 10%, 15% SDS-PAGE depending on the size of protein of interest, electrotransferred onto a nitrocellulose membrane, blocked (Blocking One, Nacalai USA, inc.) for 60 min and blotted with antibodies against Bcl-2, Bcl-xL, Cyclin-D1, PPAR-γ, procaspase-3, procaspase-9, and PARP and then detected by chemiluminescence (ECL; GE Healthcare, Little Chalfont, Buckinghamshire, UK).
RNA extraction and real-time PCR analysis
Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer"s instructions. Reverse transcription was then carried out as described previously (34) . Briefly, for a 50 μl reaction, 10 μl of RT product was mixed with 1x Taq-Man ® Universal PCR Master mix, 2.5 μl of 20x TaqMan probes for Bcl-2, Bcl-xL and cyclin D1 respectively, 2.5 μl of 20x 18S rna TaqMan probe as the endogenous control for each targeting gene, and topped up to 50 μl with sterile water. A negative control for RT, in which sterile water replaced the RNA template, was included. Another control, where RT mix was replaced with sterile water, was included to check for DNA contamination. Real-time PCR was done using 7500 Fast Real-Time PCR System (ABI PRISM 7500, Applied Biosystems, Foster City, CA, USA) with the following protocol; 50˚C for 2 min, 95˚C for 10 min, followed by 40 cycles of denaturing at 95˚C for 15 s and extension at 60˚C for 1 min. Results were analyzed using Sequence Detection Software version 1.3 provided by Applied Biosystems. Relative gene expression was obtained after normalization with endogenous human GAPDH and determination of the difference in threshold cycle (Ct) between treated and untreated cells using 2-∆∆Ct method. Primers and probes for human Bcl-2, BclxL, and cyclin D1 were purchased as kits from Applied Biosystems (Assays-onDemand). Virtual predictive studies Predictive analysis was performed using the Virtual Tumor Cell technology, Cellworks Group Inc, CA, USA which has been extensively validated and aligned with cancer physiology (34) . The Cellworks Tumor cell platform provides a dynamic and transparent view of cancer disease cellular physiology at the functional proteomics abstraction level. The platform"s openaccess architecture provides a framework for different "what-if" analysis and studies in an automated high-throughput methodology. The Cellworks platform is implemented using a three-layered architecture. The top later is a TUI/GUI (Text user interface/graphic user interface) driven user interface.
The middle layer is the comprehensive representation of signaling and metabolic pathways covering all cancer phenotypes.
The bottom layer is the computational backplane which enables the system to be dynamic and computes all the mathematics in the middle layer.
Platform description
The virtual Tumor Cell Platform consists of a dynamic and kinetic representation of the signaling pathways underlying tumor physiology at the bio-molecular level. All the key relevant protein players and associated gene and mRNA species with regard to tumor related signaling are comprehensively included in the system with their relationship quantitatively represented. Pathways and signaling for different cancer phenotypes comprise 20000 plus crosstalk with more than 8000 intracellular molecules.
The platform includes important signaling pathways comprising growth factors like EGFR, PDGFRA, FGFR, c-MET, VEGFR and IGF-1R, cell cycle regulators, mTOR signaling, p53 signaling cascade, cytokine pathways like IL1, IL4, IL6, IL12, TNF; lipid mediators and tumor metabolism. Fig.  1B shows the customized Cellworks Tumor Cell Platform that was created to align to AGS human gastric cancer cell line (KRAS mutant, PI3KCA mutant, RUNX3 deleted, β-catenin mutant and CDH1 deleted).
Predictive Study Experimental Protocol
The virtual Tumor cell is simulated in the proprietary Cellworks computational backplane and initialized to a control state wherein all molecules attain the control steady state values, following which the triggers are introduced into the system. The virtual tumor cell technology allows the end user to align the system to a known cancer cell line with perturbations in known markers or mutations that can be used for further analysis (35) . In this kinetic based virtual tumor cell platform, there is no statistical variation in the outputs. The system provides predictive semi-quantitative trends visibility into all phenotypes and biomarkers. The system predictions have been validated against a large number of retrospective and prospective studies and the accuracy of predictions is very high. Xenograft tumor model All procedures involving animals were reviewed and approved by NUS Institutional Animal Care and Use Committee. Six weekold athymic nu/nu female mice (Animal Resource Centre, Australia) were implanted subcutaneously in the right flank with SNU-5 cells (3 X 10 6 cells/100 μl saline). When tumors have reached 0.25 cm in diameter, the mice were randomized into the following treatment groups (n = 5/group) (a) untreated control (corn oil, 100 μL daily); (b) IH (1 mg/kg bodyweight, suspended in corn oil, intraperitoneal [i.p.] injection) thrice/week. Therapy was continued for 4 weeks, and the animals were euthanized 1 week later. Tumor tissues were thereafter fixed in formalin and embedded in paraffin for immunohistochemistry and routine hematoxylin and eosin (H&E) staining.
Immunohistochemical analysis of tumor tissues
Solid tumors from control and IH treated groups were fixed with 10% phosphate buffered formalin, processed and embedded in paraffin. Sections were cut and deparafinized in xylene, and dehydrated in graded alcohol and finally hydrated in water. Antigen retrieval was performed by boiling the slide in 10 mM sodium citrate (pH 6.0) for 30 min. Immunohistochemistry was performed following manufacturer instructions (DAKO LSAB kit). Briefly, endogenous peroxidases were quenched with 3% hydrogen peroxide. Non-specific binding was blocked by incubation in the blocking reagent in the LSAB kit (Dako, Carpinteria, CA) according to the manufacturer"s instructions. Sections were incubated overnight with primary antibodies as follows: anti-PPARγ, anti-Bcl-2, and anti-CD31 (each at 1:100 dilutions). Slides were subsequently washed several times in Tris buffered saline with 0.1% Tween 20 and were incubated with biotinylated linker for 30 min, followed by incubation with streptavidin conjugate provided in LSAB kit according to the manufacturer"s instructions. Immunoreactive species were detected using 3, 3-diaminobenzidine tetrahydrochloride (DAB) as a substrate. Sections were counterstained with Gill"s hematoxylin and mounted under glass cover slips. Images were taken using an Olympus BX51 microscope (magnification, 20X). Positive cells (brown) were quantitated using the Image-Pro plus 6.0 software package (Media Cybernetics, Inc.).
Statistical analysis
The data has been represented in bar graph format expressed as means ± S.E.M. from at least two independent experiments. Statistical analysis was performed by Student"s t-test and one way analysis of variance, (ANOVA). A p value of less than 0.05 (*p<0.05, **p<0.01) was considered statistically significant.
RESULTS
Predictive proteomics analysis for the effect of IH on GC cells:
Using the virtual epithelial tumour cell platform, predictive proteomics studies were conducted, and IH was represented to be an activator of PPAR-γ at tested concentrations of 0.5μM and 5μM with a K a of 1.19μM (Fig. 1C) . Interestingly, investigation of the effects of IH on anti-apoptotic genes such as Bcl-2, Bcl-xL, survivin, and Mcl1 showed a positive correlation with IH down-regulating the expression of all four genes (Fig. 1D) . Out of the two proliferative markers tested, Cyclin D1 was found to show a higher reduction as compared to Cyclin E on treatment with IH (Fig. 1E) . The impact of IH on angiogenic and metastatic markers VEGFA and CXCR4 was also studied and a reduction of ~55% and 45% with 5 μM of IH, respectively in both these markers (Fig.  1F) . Caspases-9 and 3 were found to increase on treatment with IH (Fig. 1G) . Out of the apoptotic gene products, Bak showed a higher increase when compared to Bax (Fig. 1H) . Cleaved PARP1 was found to show a very high increase of approximately 250% and ~500% with 0.5 μM and 5 μM of IH (Fig. 1I) .
IH suppresses the proliferation of GC cell lines and enhances the apoptotic effects of chemotherapeutic agents: The antiproliferative effect of IH was investigated in three GC cell lines using the MTT assay. The cells were treated for 12, 24 and 48 h with 0, 10, 25 and 50 μM concentrations of IH. IH was found to significantly inhibit the proliferation of all three GC cells in a dose and time dependent manner. Out of the three GC cell lines, AGS was found to be most sensitive to anti-proliferative effects of IH and hence selected for detailed mechanistic studies ( Fig. 2A) . Interestingly, we observed that, IH had minimal effect on the proliferation of normal gastric epithelial HFE-145 cells. Next we examined using MTT assay whether IH at sub-optimal concentration could enhance the cytotoxic effects of chemotherapeutic agents commonly employed for GC treatment. Growth inhibition rate was obtained and calculated as the percentage of dead cells versus control. Following a 24 h treatment, it was found that IH could enhance the cytotoxicity of three chemotherapeutic agents; namely, doxorubicin, capecitabine and 5-fluorouracil (Fig. 2B) . 10 µM of IH was found to enhance the cytotoxic activity of 5-fluorouracil, doxorubicin and capecitabine by 1.63, 1.89, 1.4 folds respectively. These results support the predictive analysis seen with inhibition of proliferation markers as reported in Fig. 1E . IH causes the accumulation of GC cells in the sub-G1 phase, decreases expression of anti-apoptotic proteins and induces PARP cleavage: To investigate if IH could induce apoptosis in GC cells, cell cycle distribution after PI staining was analyzed. Cells were treated with 25 µM IH for 0, 12, 24 and 48 h. Our analysis showed that IH caused increased accumulation of the cell population in the sub-G1 phase in a timedependent manner (Fig. 2C) . Under similar conditions, the expression of another apoptosis marker, phosphatidylserine distribution on the cell membrane was analyzed by flow cytometry with annexin V-FITC staining. Results showed that IH was able to increase annexin V positive cells in a time-dependent manner thus indicating induction of early apoptosis (Fig. 2D) . Whether IH could modulate the expression of various genes involved in GC survival was also determined. We found that IH could down-regulate the expression of antiapoptotic and proliferative proteins such as Bcl-2, Bcl-xL, and Cyclin D1 in a timedependent manner as observed by western blot analysis, confirming the predictive results using Cellworks Tumor Cell technology. It was further observed that IH could also down-regulate the protein levels of procaspase-9 and -3 and induce substantial PARP cleavage in GC cells (Fig.  2E) . The results indicate that IH could induce significant apoptosis in GC cells and clearly correlate with predictive results shown in Figs. 1G and J. To determine whether IH also affects the transcription of these genes, the mRNA expression of Bcl-2, Bcl-xL and Cyclin D1 was also examined. The mRNA of these genes was constitutively expressed in AGS cells and treatment with IH suppressed the expression in a time-dependent manner with maximum reduction observed after 4 h of treatment (Fig. 2F) . These results suggest that IH can modulate the expression levels of various genes involved in proliferation and survival of GC both at protein and mRNA levels. IH suppresses migration and invasion of GC cells and this property is reversed in the presence of a pharmacological PPAR-γ specific inhibitor: The effect of IH on the migratory potential of GC cells was investigated using the "wound-healing" assay. A "wound" was created with a pipette tip and the migration of cells to fill up the "wound" was recorded by microscopic observation. We found that IH alone significantly suppressed the migration of GC cells, and the pretreatment with GW9662, a pharmacological PPAR-γ inhibitor, reversed the anti-migratory effects of IH as shown in Fig. 3A .
Also, a BD biocoat tumor invasion system was used to study the effect of IH on invasion of GC cells. Upon treatment with IH, there was a reduction in the number of cells that could invade the chamber, indicating that IH could indeed significantly inhibit the invasive property of GC cells (Fig. 3B) . Moreover, we found that the pretreatment with GW9662 reversed the anti-invasive potential of IH in GC cells. IH induces activity of PPAR-γ and PPAR β/δ activity in GC cells: A reporter luciferase assay was performed to systematically study the effect of IH on the activity of various PPARs in gastric cancer cells. Cells were transfected with each of PPARs plasmids, GAL4-PPAR- LBD and GAL4-PPAR- LBD plasmids, together with GAL4-Luc and treated with IH for 18 h. It was found that IH induced the activities of both PPAR-β/δ (Fig. 4A, left panel) and PPAR-γ (Fig. 4A, right panel) . To examine the specificity of IH on the activity of PPAR-β/δ and PPAR-γ, luciferase assay was performed in the presence of their respective antagonists. It was found that GSK0660, an antagonist of PPAR-β/δ, was unable to reverse IH-induced PPAR-β/δ activity (Fig.  4B, left panel) , while similar concentrations of GSK0660 could reverse the effect of GW0472, a proven PPAR-β/δ agonist (Fig.  4B, right panel) suggesting that the effect of IH on PPAR-β/δ was not specific. However, the antagonist of PPAR-γ, GW9662, could significantly reverse IH-induced PPAR-γ activity (Fig. 4C, left panel) as well as activity of 15d-PGJ 2 , a classical PPAR-γ agonist. (Fig. 4C, right panel) , thereby suggesting that the anticancer effects of IH may be mediated through PPAR-γ pathway.
IH induces PPAR-γ activity in GC cells:
Due to the specific effect of IH on PPAR-γ activity in GC cells, and in view of the fact that PPAR-γ has been extensively shown to be associated with anticancer effects in a variety of cancer types including GC, we choose to focus on this isoform and its potential role in the observed anti-cancer effects of IH. First, the molecular docking of IH to PPAR-γ using the Dock feature in Molecular Operating Environment (MOE) was performed as described in Materials and Methods. IH was able to form interactions with 7 polar residues and 6 non-polar residues in the receptor within the ligandbinding pocket of PPAR-γ that were reported to be critical for its activity (Fig.  5A, left panel) . The 3D conformational structure of IH inside PPAR-γ is shown in (Fig. 5A, right panel) . The dose-and timedependent effect of IH on PPAR-γ activity in GC cells was also determined. AGS cells were pre-transfected with pPPRE-tk-Luc and β-gal plasmids, followed by treatment with different concentrations of IH for 8 h. After normalization with the vehicle control, it was found that IH could significantly increase PPAR-γ activity and expression in a dose-dependent manner, with maximum effect at 50 µM concentration (Fig. 5B, left  panel) . IH also increased PPAR-γ activity in a time-dependent manner, with maximum activity recorded at 8h (Fig. 5B, right panel) .
Also, an in-vitro binding assay was performed to determine if IH could competitively bind to PPARγ. Serial dilutions of IH were prepared in a 384-well polypropylene assay plate. Fluormone™ Pan-PPAR Green, PPARγ-LBD, and Tbanti-GST Ab were then added to each sample well as described in the protocol. The assay mixture was incubated for one h at room temperature prior to measuring the 520 nm/490 nm emission ratio of each well. Error bars represent the SEM of duplicate wells (n=2). The results, as shown in Fig. 5C clearly indicate that IH could indeed bind competitively to PPAR-γ with an IC50 of 5.98 µM.
GW9662, a pharmacological PPAR-γ inhibitor, reversed the effect of IH on apoptosis:
To determine if the increase in apoptosis was due to IH-induced PPAR-γ activity, GW9662, a pharmacological PPAR-γ inhibitor, was used to block the activation of the PPAR-γ pathway. AGS cells were pretreated GW9662 for 2 h followed by IH exposure for 18 h. GW9662 significantly reversed IH-induced PPAR-γ activity (Fig.  6A , left panel) similar to its activity in the presence of a proven PPAR-γ agonist, 15d-PGJ2 (15) (Fig. 6A, right panel) . IH-induced apoptosis was found to be reversed by GW9662, though not completely as observed by annexin-V assay (Fig. 6B, left  panel) . Transfection efficiency was monitored by western blot analysis (Fig. 6B,  right panel) . These findings suggest that PPAR-γ is involved in IH-induced apoptosis, at least to a partial extent.
PPAR-γ dominant negative impaired the effect of IH on the PPAR-γ pathway:
The induction of PPAR-γ activity by IH was also investigated through a genomic approach. Faulty PPAR-γ nuclear receptor was overexpressed to reduce the chance of IH binding. It was found that the induction of PPAR-γ activity in AGS cells by IH was significantly reversed in the presence of PPAR-γ dominant negative as observed by luciferase assay results (Fig. 6C, left panel) . Transfection efficiency was monitored by western blot analysis (Fig. 6B, right panel) .
IH increases the expression of PPAR-γ in gastric tumor tissues:
We also evaluated the effect of IH on PPAR-γ levels in GC tissue. Fig. 6D shows that IH was quite effective in increasing the expression of PPAR-γ in GC tissues.
Whether IH can modulate the expression of gene products involved in anti-apoptosis (Bcl-2) and angiogenesis (CD31) in GC tissues, was also examined. We found that treatment with IH was effective in significantly down regulating the overexpression of Bcl-2 and CD31 in GC tissue samples (Fig. 6D) .
DISCUSSION
The aim of this study was to determine whether IH exerts its anti-cancer effects in GC cells through the modulation of PPAR-γ signaling pathway. We observed that this flavonoid increased PPAR-γ activity, and modulated the expression of the PPAR-γ regulated genes in GC cells. Also, the increase in PPAR-γ activity by IH could be reversed in the presence of PPAR-γ pharmacological blocker and a mutated PPAR-γ dominant negative plasmid, thereby indicating that IH can act as a potential novel ligand of PPAR-γ. We further observed that IH could form interactions with 7 polar residues and 6 non-polar residues within the ligand-binding pocket of PPAR-γ that are reported to be critical for its activity and also competitively bind to PPAR-γ. IH also caused the inhibition of proliferation, induced apoptosis, as evident by PARP cleavage, and also potentiated the apoptotic effects of chemotherapeutic drugs in GC cells. This hypothesis was also tested in a virtual predictive tumor cell system and 0.5μM and 5μM with a K a of 1.19μM concentrations of IH caused PPAR-γ activation and generated similar biomarker trends as seen experimentally with IH effects on GC cells.
Intra-peritoneal injection of IH into nude mice bearing subcutaneous SNU-5 xenografts resulted in significant increase in the expression of PPAR-γ and the downmodulation of Bcl-2 and CD31 in treated tumor tissues.
The most important characteristic of a cancer cell remains its ability to sustain proliferation (37) . The cellular pathways that control proliferation in normal cells are perturbed in most cancers (38) . According to Prof. Weinberg in his classical "Hallmarks of Cancer", tumor cells can proliferate using alternate strategies; autocrine signaling through which they might produce growth factors themselves and respond to it with their own cognate receptors or by manipulating normal cells in providing them with growth factors (39) . Thus, we first analyzed the effect of IH on the proliferation of GC cells. Our results clearly showed that IH could indeed inhibit the proliferation of three GC cell lines, (AGS, SNU5 and MKN45) in a dose and time dependent manner. It is interesting to note that though IH could inhibit the proliferation of various GC cells, it showed minimal effect on the proliferation of normal GC cells, thereby indicating that it is not substantially cytotoxic to normal cells. We also show for the first time that IH can enhance the cytotoxic effects of chemotherapeutic agents commonly employed in GC treatment. Together, these results suggest that IH can be used as a complement to conventional chemotherapeutic drugs for the purpose of enhancing the anti-tumor effect and/or reducing toxicity of the latter.
To understand the mechanism of how IH exerts its growth inhibitory effects, we evaluated its effect on the apoptosis in GC cells. We found that IH was able to induce significant apoptosis concomitant with down-regulation in the expression of the various antiapoptotic/antiproliferative proteins (Bcl-2, Bcl-xL, and Cyclin-D1), increase in the expression of procaspase-9/3 and caused PARP cleavage in a time dependent manner in GC cells.
Cancer metastasis refers to the spread of cancer cells from the primary neoplasm to distant sites, where secondary tumors are formed, and is considered one of the major causes of cancer mortality (40) (41) (42) . Therefore, we also analyzed the effect of IH on the GC migration and invasion and our study is the first to demonstrate that IH could inhibit the migratory and invasive properties of GC cells. These effects could also be reversed in the presence of a pharmacological PPAR-γ inhibitor, thereby indicating that the anti-migratory/invasive effects of IH may be mediated through the activation of PPAR-γ signaling pathway.
Next, we decided to elucidate the molecular mechanisms underlying the observed anti-cancer effects of IH and investigated its effect on the activation of master transcription factor PPAR-γ, a nuclear receptor reported to play an important role in the initiation and development of GC (43) . In a study to elucidate the role of PPAR-γ in GC, it was found that the loss of the receptor promoted gastric carcinogenesis (44) . PPAR-γ has been reported to be expressed in high levels in GC and it was shown that activated PPAR-γ could induce apoptosis in GC cells (45) . In our study, we found that IH could physically interact with PPAR-γ at 5 polar residues and 9 non-polar residues out of which two interactions, Cys285 and Ser289 were previously found to be important for its binding and activity (46) (47) (48) . We also observed that IH can activate PPAR-γ in a time and dose-dependent manner and can competitively bind to the receptor with increasing concentrations. Interestingly, IHinduced apoptosis could be inhibited by PPAR-γ antagonist, GW9662 thereby indicating that the anti-cancer effects of IH may be mediated through the PPAR-γ activation pathway. The results obtained from the virtual technology platform also supported our hypothesis that IH could indeed activate PPARγ and could modulate various gene products involved in proliferation, survival and metastasis of GC.
Whether these in vitro observations with IH have any relevance under in vivo settings was also investigated. Our results also indicate for the first time that IH can indeed significantly increase the expression of PPAR-γ and downregulate the expression Bcl-2 and CD31 in treated tumor tissues as compared to control group. To the best of our knowledge, no prior studies with IH in xenograft GC models have been reported so far, and our overall findings suggest that IH has a tremendous potential for the treatment of GC. IH has been reported to exhibit significant anti-inflammatory, antiproliferative, pro-apoptotic and chemopreventive effects in selected tumor cells and mice models. However, it has never been tested in humans before and hence its clinically relevant doses are not known as yet. Further studies in humans are required before its clinical potential is fully realized in cancer treatment. Thus, overall, our experimental and predictive experiment results clearly indicate that anti-proliferative and pro-apoptotic effects of IH in GC are mediated through activation of PPAR-γ and provide a sound basis for pursuing the use of IH further, either alone or in combination with existing therapy, to reduce the side effects and enhance treatment efficacy for GC.
FOOTNOTES
Abbreviations used: GC, gastric cancer; 15d-PGJ2, 15-deoxy-Δ12, 14-prostaglandin J2; RXR, retinoid X receptor; PPRE, peroxisome proliferator response element; AFB1, aflatoxin B1, PI: propidium iodide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; FBS, fetal bovine serum; MOE, molecular operating environment; EDTA, Ethylenediaminetetraacetic acid; TR-FRET, time-resolved fluorescence resonance energy transfer; NR, nuclear receptor; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; Bcl-2, B cell lymphoma-2; Bcl-xL, Bcl-2 like protein 1; TUI/GUI: text user interface/graphic user interface; EGFR,epidermal growth factor receptor; PDGFRA, plateletderived growth factor receptor, alpha polypeptide; FGFR, fibroblast growth factor receptor; VEGFR,vascular endothelial growth factor; DMEM, Dulbecco's Modified Eagle Medium; RPMI, Roswell Park Memorial Institute medium; FBS, fetal bovine serum; PBS, phosphate buffered saline; PMSF, phenylmethanesulfonylfluoride; RT, reverse transcriptase; DNA, deoxyribonucleic acid; IGF-1R, insulin-like growth factor 1 receptor; IL1, Interleukin-1; IL4, Interleukin-4; IL6, Interleukin-6; IL12, Interleukin-12; TNF, tumour necrosis factor; mTOR, mammalian target of rapamycin; CD31, cluster of differentiation 31; DMSO, dimethyl sulfoxide; GST, glutatione Stransferase; LBD, ligand binding domain; CXCR4, C-X-C chemokine receptor type 4; KRAS, kirsten rat sarcoma viral oncogene homolog; PI3KCA, phosphatidyl inositol 3-kinase catalytic subunit; RUNX3, runt-related transcription factor 3; CDH1, cadherin 1; MCL1, myeloid cell leukemia sequence 1 (BCL2-related); FITC, fluorescein isothiocyanate; PARP, poly(ADPribose)polymerase;
Key words: Isorhamnetin, gastric cancer, peroxisome proliferator activated receptor, apoptosis. The data are representative of at least three independent experiments. (F) AGS cells were treated with 25 µM IH for the indicated time intervals, after which cells were harvested and RNA samples were extracted. 1µg portions of the respective RNA extracts were subjected to reverse transcription to generate corresponding cDNA. Real time PCR was performed to measure the relative quantities of mRNA. Each RT product was targeted against Bcl-2, Bcl-xL, and cyclin D1 TaqMan probes, with HuGAPDH as endogenous control for measurement of equal loading of RNA samples. Results were analyzed using Sequence Detection Software version 1.3 provided by Applied Biosystems. *p<0.05, **p<0.01 . IH also increases PPAR-γ activity in a timedependent manner (right panel). Cells were transfected with pPPRE-tk-Luc and β-gal plasmid for 4h before treatment with the indicated concentrations of IH. The data are expressed as percentages of the PPAR-γ activity relative to the control. Values are means ± S.E.M. of two or three independent experiments, *p<0.05, **p<0.01. (C) In-vitro competitive binding assay showed that IH could bind competitively to PPARγ. Serial dilutions of IH (1% final DMSO concentration, serial dilutions performed in 100% DMSO) were prepared in a 384-well polypropylene assay plate. Fluormone™ Pan-PPAR Green, PPARγ-LBD, and Tb-anti-GST Ab were then added to each sample well as described in the protocol. The assay mixture was incubated for one h at room temperature prior to measuring the 520 nm/490 nm emission ratio of each well. Error bars represent the SEM of duplicate wells (n=2). 
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